NCT05246033 - A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

March 15, 2023

Study Completion Date

March 31, 2024

Conditions

Achondroplasia

Interventions

DRUG

TransCon CNP

TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

DRUG

Placebo for TransCon CNP

Weekly subcutaneously injection of placebo.

Trial Locations (5)

20082

Ascendis Pharma Investigational Site, Shanghai

100045

Ascendis Pharma Investigational Site, Beijing

310053

Ascendis Pharma Investigational Site, Hangzhou

430030

Ascendis Pharma Investigational Site, Wuhan

510080

Ascendis Pharma Investigational Site, Guangzhou